32813-35-7 Usage
Description
3-(4-Ethyl-piperidin-1-yl)-propylamine is an organic compound with the molecular formula C10H22N2. It is a derivative of piperidine, a heterocyclic amine, and features an ethyl group and a propylamine group attached to the piperidine ring. 3-(4-ETHYL-PIPERIDIN-1-YL)-PROPYLAMINE is known for its potential applications in the pharmaceutical industry due to its unique structural properties and interactions with biological systems.
Uses
Used in Pharmaceutical Industry:
3-(4-Ethyl-piperidin-1-yl)-propylamine is used as an intermediate compound for the synthesis of various pharmaceutical products. Its unique structure allows it to be a key component in the development of new drugs targeting specific medical conditions.
Used in Preparation of Salicylamide Compound:
3-(4-Ethyl-piperidin-1-yl)-propylamine is used as a key component in the preparation of Salicylamide compound, which is utilized for treating nervous system-related diseases. 3-(4-ETHYL-PIPERIDIN-1-YL)-PROPYLAMINE's interaction with the nervous system makes it a valuable asset in the development of therapeutic agents for conditions such as pain, inflammation, and other neurological disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 32813-35-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,2,8,1 and 3 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 32813-35:
(7*3)+(6*2)+(5*8)+(4*1)+(3*3)+(2*3)+(1*5)=97
97 % 10 = 7
So 32813-35-7 is a valid CAS Registry Number.
32813-35-7Relevant articles and documents
THIENOPYRIDINONE COMPOUNDS AND METHODS OF TREATMENT
-
Page/Page column 17, (2008/06/13)
The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.
